|
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
||
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
Item 1.01. |
Entry into a Material Definitive Agreement
|
BridgeBio Pharma, Inc.
|
|||
Date:
|
March 4, 2024
|
By:
|
/s/ Brian C. Stephenson
|
Brian C. Stephenson
|
|||
Chief Financial Officer
|
Document and Entity Information |
Mar. 01, 2024 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Amendment Flag | false |
Document Period End Date | Mar. 01, 2024 |
Entity File Number | 001-38959 |
Entity Registrant Name | BridgeBio Pharma, Inc. |
Entity Central Index Key | 0001743881 |
Entity Incorporation, State or Country Code | DE |
Entity Tax Identification Number | 84-1850815 |
Entity Address, Address Line One | 3160 Porter Dr. |
Entity Address, Address Line Two | Suite 250 |
Entity Address, City or Town | Palo Alto |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94304 |
City Area Code | 650 |
Local Phone Number | 391-9740 |
Title of 12(b) Security | Common Stock, par value $0.001 per share |
Trading Symbol | BBIO |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
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end
S,;1BC+B)\'\C@]2H4)G
MKB?4-+L\DZV)Y?1$=M.G]GEL53HK_R!RCR;!#_,?D1#L^8EL746(.8LR@JIJ
M\RQV6T$]('A)[FC(WU=W^[R